Induction of Cyclooxygenase-2 in Human Saphenous Vein and Internal Mammary Artery
- 1 September 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 17 (9) , 1644-1648
Abstract
Within vessels, cyclooxygenase (COX) is expressed constitutively (COX-1) in endothelial cells where its production of prostacyclin is thought to contribute to the maintenance of vascular integrity. Recently, a novel isoform of COX, COX-2, has been described that is induced in animal arterial vessels after physical damage or exposure to proinflammatory cytokines. However, induction of COX-2 in human vessels has not been characterized. Moreover, the relative ability of arteries and veins to express COX-2 has not been addressed. Thus, we have compared the ability of segments of human saphenous vein and internal mammary artery, obtained from the same patient, to express COX-2 activity and mRNA after organ culture in the presence and absence of interleukin-1β. COX-2 metabolites, measured by radioimmunoassay, were released by both the internal mammary artery and saphenous vein in the following rank order: prostaglandin E2≥prostacyclin thromboxane A2. Inclusion of interleukin-1β in the culture medium increased the release of prostanoids by the saphenous vein but not by the internal mammary artery. However, the selective COX-2 inhibitor NS-398 significantly attenuated prostacyclin release from both tissues. Northern blot analysis showed no detectable COX-2 mRNA in freshly prepared saphenous vein or internal mammary artery. In contrast, after 48 hours in organ culture, low levels of COX-2 mRNA were detected in both internal mammary artery and saphenous vein, an effect that was greatly increased by interleukin-1β. These observations show that COX-2 is induced in human saphenous vein and internal mammary artery and suggest that this may occur in humans after coronary artery bypass graft surgery. The induction of COX-2 and subsequent release of prostacyclin may represent an endogenous defense mechanism against endothelial damage incurred during surgical preparation of these vessels for bypass.Keywords
This publication has 25 references indexed in Scilit:
- Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor.Journal of Clinical Investigation, 1996
- Overexpression of Prostacyclin Synthase Inhibits Growth of Vascular Smooth Muscle CellsBiochemical and Biophysical Research Communications, 1995
- Comparison of response to injury in organ culture of human saphenous vein and internal mammary arteryThe Annals of Thoracic Surgery, 1993
- Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids.Journal of Clinical Investigation, 1988
- Suppression of principal atherosclerotic mechanisms by prostacyclinc and other eicosanoidsProgress in Lipid Research, 1986
- Effects of isolation and culture on prostaglandin synthesis by porcine aortic endothelial and smooth muscle cellsJournal of Cellular Physiology, 1982
- Recovery of prostacyclin production by de-endothelialized rabbit aorta. Critical role of neointimal smooth muscle cells.Journal of Clinical Investigation, 1981
- Prostaglandin E2 biosynthesis and effect in pigeon aorta possible role in atherogenesisAtherosclerosis, 1978
- Inhibition of cholesterol esterification in rabbit aorta by prostaglandin E2Atherosclerosis, 1977
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976